Johannes Schmoellerl, postdoctoral researcher with Johannes Zuber, is awarded one of 30 “Disruptive Innovation Grants” to study therapy resistance of an aggressive type of blood cancer. The new funding scheme of the Austrian science fund FWF and the Academy of Sciences aims to support innovative ideas of early career researchers.